Synaptogenix’s Bryostatin-1 in Alzheimer’s featured in peer-reviewed publication

Synaptogenix announced a peer-reviewed publication of statistically significant integration of secondary and exploratory endpoint data from its previously completed Phase 2 trial of Bryostatin-1 for Alzheimer’s disease. As stated in the paper, conclusions from analyses of the trial’s Severe Cohort indicate that Bryostatin-treated MMSE 10-14 patients showed no significant cognitive decline throughout the 10-month trial, compared with placebo patients’ decline of -12.8 SIB points. The paper goes on to discuss persistence in the data, stating, “The prolonged absence of any significant cognitive decline in Bryostatin-treated patients vs. placebo patients – even 16 weeks after the final dose of Bryostatin – suggests a long-lasting positive change in the treated patients’ brains.” The data demonstrates that Bryostatin-1-treated patients in the Severe Cohort showed statistically significant improvement of cognitive performance over placebo patients for weeks #13 through #42, with the last dose administered at Week #26.